ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have earned a consensus rating of “Buy” from the five brokerages that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.60.

PRQR has been the subject of several research reports. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th.

ProQR Therapeutics Price Performance

PRQR opened at $2.57 on Thursday. The company’s 50 day simple moving average is $3.45 and its 200-day simple moving average is $2.41. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The stock has a market capitalization of $209.92 million, a P/E ratio of -8.03 and a beta of 0.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. OneDigital Investment Advisors LLC grew its position in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets increased its position in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after acquiring an additional 236,279 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).